Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Expression of Immune System-Related Membrane Receptors CD40, RANK, BAFFR and LTβR is Associated with Clinical Outcome of Operated Non-Small-Cell Lung Cancer Patients.

Dimitrakopoulos FD, Kottorou AE, Antonacopoulou AG, Panagopoulos N, Scopa C, Kalofonou M, Dougenis D, Koutras A, Makatsoris T, Tzelepi V, Kalofonos HP.

J Clin Med. 2019 May 24;8(5). pii: E741. doi: 10.3390/jcm8050741.

2.

The Impact of Anti-tumor Agents on ER-Positive MCF-7 and HER2-Positive SKBR-3 Breast Cancer Cells Biomechanics.

Metsiou DN, Siatis KE, Giannopoulou E, Papachristou DJ, Kalofonos HP, Koutras A, Athanassiou G.

Ann Biomed Eng. 2019 May 16. doi: 10.1007/s10439-019-02284-3. [Epub ahead of print]

PMID:
31098800
3.

Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity.

Cavaletti G, Cornblath DR, Merkies ISJ, Postma TJ, Rossi E, Alberti P, Bruna J, Argyriou AA, Briani C, Velasco R, Kalofonos HP, Psimaras D, Ricard D, Pace A, Faber CG, Lalisang RI, Brandsma D, Koeppen S, Kerrigan S, Schenone A, Grisold W, Mazzeo A, Padua L, Dorsey SG, Penas-Prado M, Valsecchi MG; CI-PeriNomS Group.

J Peripher Nerv Syst. 2019 Mar;24(1):111-119. doi: 10.1111/jns.12306. Epub 2019 Feb 8.

PMID:
30672664
4.

Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.

Koutras A, Lazaridis G, Koliou GA, Kouvatseas G, Christodoulou C, Pectasides D, Kotoula V, Batistatou A, Bobos M, Tsolaki E, Papadopoulou K, Pentheroudakis G, Papakostas P, Pervana S, Petraki K, Chrisafi S, Razis E, Psyrri A, Bafaloukos D, Kalogeras KT, Kalofonos HP, Fountzilas G.

PLoS One. 2018 Dec 6;13(12):e0207707. doi: 10.1371/journal.pone.0207707. eCollection 2018.

5.

Development of a validated LC-MS/MS method for the in vitro and in vivo quantitation of sunitinib in glioblastoma cells and cancer patients.

Chatziathanasiadou MV, Stylos EK, Giannopoulou E, Spyridaki MH, Briasoulis E, Kalofonos HP, Crook T, Syed N, Sivolapenko GB, Tzakos AG.

J Pharm Biomed Anal. 2019 Feb 5;164:690-697. doi: 10.1016/j.jpba.2018.11.030. Epub 2018 Nov 14.

PMID:
30472587
6.

Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab.

Christodoulou C, Oikonomopoulos G, Koliou GA, Kostopoulos I, Kotoula V, Bobos M, Pentheroudakis G, Lazaridis G, Skondra M, Chrisafi S, Koutras A, Bafaloukos D, Razis E, Papadopoulou K, Papakostas P, Kalofonos HP, Pectasides D, Skarlos P, Kalogeras KT, Fountzilas G.

Cancer Genomics Proteomics. 2018 Nov-Dec;15(6):461-471. doi: 10.21873/cgp.20105.

7.

Development of a novel conjugatable sunitinib analogue validated through in vitro and in vivo preclinical settings.

El Mubarak MA, Leontari I, Efstathia G, Vrettos EI, Shaikh AK, Konstantinos SE, Danika C, Kalofonos HP, Tzakos AG, Sivolapenko GB.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Aug 15;1092:515-523. doi: 10.1016/j.jchromb.2018.05.050. Epub 2018 Jun 2.

PMID:
30008308
8.

Correction to: Identification of novel human RANK isoforms generated through alternative splicing. Implications in breast cancer cell survival and migration.

Papanastasiou AD, Sirinian C, Kalofonos HP.

Breast Cancer Res. 2018 Jun 7;20(1):47. doi: 10.1186/s13058-018-0985-z.

9.

RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF-κB activation and EGFR signaling.

Sirinian C, Papanastasiou AD, Schizas M, Spella M, Stathopoulos GT, Repanti M, Zarkadis IK, King TA, Kalofonos HP.

Oncogene. 2018 Sep;37(37):5101-5114. doi: 10.1038/s41388-018-0324-y. Epub 2018 May 29.

PMID:
29844572
10.

Deregulation of methylation of transcribed-ultra conserved regions in colorectal cancer and their value for detection of adenomas and adenocarcinomas.

Kottorou AE, Antonacopoulou AG, Dimitrakopoulos FD, Diamantopoulou G, Sirinian C, Kalofonou M, Theodorakopoulos T, Oikonomou C, Katsakoulis EC, Koutras A, Makatsoris T, Demopoulos N, Stephanou G, Stavropoulos M, Thomopoulos KC, Kalofonos HP.

Oncotarget. 2018 Apr 20;9(30):21411-21428. doi: 10.18632/oncotarget.25115. eCollection 2018 Apr 20.

11.

Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve.

Alberti P, Rossi E, Argyriou AA, Kalofonos HP, Briani C, Cacciavillani M, Campagnolo M, Bruna J, Velasco R, Cazzaniga ME, Cortinovis D, Valsecchi MG, Cavaletti G.

Support Care Cancer. 2018 Sep;26(9):3143-3151. doi: 10.1007/s00520-018-4170-9. Epub 2018 Mar 29.

PMID:
29594485
12.

NF-kB2 Genetic Variations are Significantly Associated with Non-Small Cell Lung Cancer Risk and Overall Survival.

Dimitrakopoulos FD, Antonacopoulou AG, Kottorou AE, Maroussi S, Panagopoulos N, Koukourikou I, Scopa C, Kalofonou M, Koutras A, Makatsoris T, Papadaki H, Dougenis D, Brock M, Kalofonos HP.

Sci Rep. 2018 Mar 27;8(1):5259. doi: 10.1038/s41598-018-23324-3.

13.

ILK Expression in Colorectal Cancer Is Associated with EMT, Cancer Stem Cell Markers and Chemoresistance.

Tsoumas D, Nikou S, Giannopoulou E, Champeris Tsaniras S, Sirinian C, Maroulis I, Taraviras S, Zolota V, Kalofonos HP, Bravou V.

Cancer Genomics Proteomics. 2018 Mar-Apr;15(2):127-141.

14.

LIMK/cofilin pathway and Slingshot are implicated in human colorectal cancer progression and chemoresistance.

Aggelou H, Chadla P, Nikou S, Karteri S, Maroulis I, Kalofonos HP, Papadaki H, Bravou V.

Virchows Arch. 2018 May;472(5):727-737. doi: 10.1007/s00428-018-2298-0. Epub 2018 Jan 19.

PMID:
29352327
15.

RANK and EGFR in invasive breast carcinoma.

Papanastasiou AD, Sirinian C, Plakoula E, Zolota V, Zarkadis IK, Kalofonos HP.

Cancer Genet. 2017 Oct;216-217:61-66. doi: 10.1016/j.cancergen.2017.07.004. Epub 2017 Jul 26.

PMID:
29025596
16.

Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial.

Bruna J, Videla S, Argyriou AA, Velasco R, Villoria J, Santos C, Nadal C, Cavaletti G, Alberti P, Briani C, Kalofonos HP, Cortinovis D, Sust M, Vaqué A, Klein T, Plata-Salamán C.

Neurotherapeutics. 2018 Jan;15(1):178-189. doi: 10.1007/s13311-017-0572-5.

17.

Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.

Griffith KA, Zhu S, Johantgen M, Kessler MD, Renn C, Beutler AS, Kanwar R, Ambulos N, Cavaletti G, Bruna J, Briani C, Argyriou AA, Kalofonos HP, Yerges-Armstrong LM, Dorsey SG.

J Pain Symptom Manage. 2017 Nov;54(5):701-706.e1. doi: 10.1016/j.jpainsymman.2017.07.033. Epub 2017 Jul 23.

18.

Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20).

Kieffer JM, Postma TJ, van de Poll-Franse L, Mols F, Heimans JJ, Cavaletti G, Aaronson NK; CI-PeriNomS Group.

Qual Life Res. 2017 Nov;26(11):2999-3010. doi: 10.1007/s11136-017-1626-1. Epub 2017 Jun 20.

PMID:
28634676
19.

The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy.

Gavressea T, Kalogeras KT, Koliou GA, Zagouri F, Lazaridis G, Gogas H, Tsigaridas K, Koutras A, Petraki K, Markopoulos C, Pazarli E, Aravantinos G, Papadimitriou C, Papakostas P, Koufopoulos N, Karanikiotis C, Chrisafi S, Kalofonos HP, Pectasides D, Fountzilas G, Pavlakis K.

Anticancer Res. 2017 Jun;37(6):2947-2957.

PMID:
28551632
20.

Long-term disease stabilization following treatment with erlotinib in heavily pretreated patients with wild-type epidermal growth factor receptor non-small-cell lung carcinoma: Two case reports.

Sakellakis M, Koutras A, Pittaka M, Tsitsopoulos E, Kalofonou F, Kalofonos HP.

Mol Clin Oncol. 2016 Dec;5(6):803-806. doi: 10.3892/mco.2016.1036. Epub 2016 Sep 26.

21.

Follicle-Stimulating Hormone Receptor (FSHR): A Promising Tool in Oncology?

Papadimitriou K, Kountourakis P, Kottorou AE, Antonacopoulou AG, Rolfo C, Peeters M, Kalofonos HP.

Mol Diagn Ther. 2016 Dec;20(6):523-530. Review.

PMID:
27392476
22.

Lack of association of the M129V polymorphism of the PRNP gene with pseudoexfoliation syndrome.

Giannakopoulos MP, Antonacopoulou AG, Kottorou AE, Kalofonos HP, Gartaganis SP.

Clin Ophthalmol. 2016 Apr 22;10:731-4. doi: 10.2147/OPTH.S92174. eCollection 2016.

23.

Identification of a seasonal pattern to brain metastases.

Sakellakis M, Koutras A, Pittaka M, Kardamakis D, Kalofonou M, Kalofonos HP, Spyropoulou D.

Neuropsychiatr Dis Treat. 2016 Mar 7;12:609-10. doi: 10.2147/NDT.S104261. eCollection 2016. No abstract available.

24.

Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia.

Mountzios G, Aravantinos G, Alexopoulou Z, Timotheadou E, Matsiakou F, Christodoulou C, Laschos K, Galani E, Koutras A, Bafaloukos D, Linardou H, Pectasides D, Varthalitis I, Papakostas P, Kalofonos HP, Fountzilas G.

Mol Clin Oncol. 2016 Feb;4(2):211-220. Epub 2015 Dec 4.

25.

Epidermal growth factor receptor status and Notch inhibition in non-small cell lung cancer cells.

Giannopoulou E, Nikolakopoulos A, Kotsirilou D, Lampropoulou A, Raftopoulou S, Papadimitriou E, Theocharis AD, Makatsoris T, Fasseas K, Kalofonos HP.

J Biomed Sci. 2015 Oct 24;22:98. doi: 10.1186/s12929-015-0196-1.

26.

Early-Stage Breast Cancer in the Elderly: Confronting an Old Clinical Problem.

Dimitrakopoulos FI, Kottorou A, Antonacopoulou AG, Makatsoris T, Kalofonos HP.

J Breast Cancer. 2015 Sep;18(3):207-17. doi: 10.4048/jbc.2015.18.3.207. Epub 2015 Sep 24. Review.

27.

Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc(©) ) in patients with chemotherapy-induced peripheral neuropathy.

Binda D, Cavaletti G, Cornblath DR, Merkies IS; CI-PeriNomS study group.

J Peripher Nerv Syst. 2015 Sep;20(3):328-32. doi: 10.1111/jns.12140.

PMID:
26306547
28.

Expression of the microRNA regulators Drosha, Dicer and Ago2 in non-small cell lung carcinomas.

Prodromaki E, Korpetinou A, Giannopoulou E, Vlotinou E, Chatziathanasiadou Μ, Papachristou NI, Scopa CD, Papadaki H, Kalofonos HP, Papachristou DJ.

Cell Oncol (Dordr). 2015 Aug;38(4):307-17. doi: 10.1007/s13402-015-0231-y. Epub 2015 Jul 31.

PMID:
26227789
29.

Variant of BCL3 gene is strongly associated with five-year survival of non-small-cell lung cancer patients.

Dimitrakopoulos FI, Antonacopoulou AG, Kottorou A, Marousi S, Koukourikou I, Kalofonou M, Panagopoulos N, Scopa C, Dougenis D, Papadaki H, Papavassiliou AG, Kalofonos HP.

Lung Cancer. 2015 Sep;89(3):311-9. doi: 10.1016/j.lungcan.2015.06.006. Epub 2015 Jun 20.

PMID:
26122346
30.

Focal Adhesion Proteins α- and β-Parvin are Overexpressed in Human Colorectal Cancer and Correlate with Tumor Progression.

Bravou V, Antonacopoulou A, Papanikolaou S, Nikou S, Lilis I, Giannopoulou E, Kalofonos HP.

Cancer Invest. 2015;33(8):387-97. doi: 10.3109/07357907.2015.1047508. Epub 2015 Jun 26.

PMID:
26115385
31.

Identification of cancer predisposition variants in apparently healthy individuals using a next-generation sequencing-based family genomics approach.

Karageorgos I, Mizzi C, Giannopoulou E, Pavlidis C, Peters BA, Zagoriti Z, Stenson PD, Mitropoulos K, Borg J, Kalofonos HP, Drmanac R, Stubbs A, van der Spek P, Cooper DN, Katsila T, Patrinos GP.

Hum Genomics. 2015 Jun 20;9:12. doi: 10.1186/s40246-015-0034-2.

32.

Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.

Koutras A, Kalogeras KT, Wirtz RM, Alexopoulou Z, Bobos M, Zagouri F, Veltrup E, Timotheadou E, Gogas H, Pentheroudakis G, Pisanidis N, Magkou C, Christodoulou C, Bafaloukos D, Papakostas P, Aravantinos G, Pectasides D, Kalofonos HP, Fountzilas G.

J Transl Med. 2015 May 29;13:171. doi: 10.1186/s12967-015-0530-0.

33.

Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.

Pectasides D, Karavasilis V, Papaxoinis G, Gourgioti G, Makatsoris T, Raptou G, Vrettou E, Sgouros J, Samantas E, Basdanis G, Papakostas P, Bafaloukos D, Kotoula V, Kalofonos HP, Scopa CD, Pentheroudakis G, Fountzilas G.

BMC Cancer. 2015 May 10;15:384. doi: 10.1186/s12885-015-1406-7.

34.

PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.

Koumarianou A, Karayannopoulou G, Gourgioti G, Batistatou A, Bobos M, Efstratiou I, Miliaras D, Galani E, Pentheroudakis G, Pectasides D, Aravantinos G, Bafaloukos D, Papakostas P, Razis E, Kalofonos HP, Petraki K, Sotiropoulou M, Kalogeras KT, Fountzilas G.

Cancer Chemother Pharmacol. 2015 Jun;75(6):1289-301. doi: 10.1007/s00280-015-2762-3. Epub 2015 May 7.

PMID:
25947084
35.

Regioselective chemical and rapid enzymatic synthesis of a novel redox – Antiproliferative molecular hybrid.

Geromichalou E, Sayyad N, Kyriakou E, Chatzikonstantinou AV, Giannopoulou E, Vrbjar N, Kalofonos HP, Stamatis H, Tzakos AG.

Eur J Med Chem. 2015;96:47-57. doi: 10.1016/j.ejmech.2015.03.064. Epub 2015 Apr 2.

PMID:
25874330
36.

Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis.

Terrazzino S, Argyriou AA, Cargnin S, Antonacopoulou AG, Briani C, Bruna J, Velasco R, Alberti P, Campagnolo M, Lonardi S, Cortinovis D, Cazzaniga M, Santos C, Kalofonos HP, Canonico PL, Genazzani AA, Cavaletti G.

J Peripher Nerv Syst. 2015 Mar;20(1):15-23. doi: 10.1111/jns.12110.

PMID:
25858589
37.

A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients.

Panoilia E, Schindler E, Samantas E, Aravantinos G, Kalofonos HP, Christodoulou C, Patrinos GP, Friberg LE, Sivolapenko G.

Cancer Chemother Pharmacol. 2015 Apr;75(4):791-803. doi: 10.1007/s00280-015-2701-3. Epub 2015 Feb 17.

38.

Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.

Briani C, Argyriou AA, Izquierdo C, Velasco R, Campagnolo M, Alberti P, Frigeni B, Cacciavillani M, Bergamo F, Cortinovis D, Cazzaniga M, Bruna J, Cavaletti G, Kalofonos HP.

J Peripher Nerv Syst. 2014 Dec;19(4):299-306. doi: 10.1111/jns.12097.

PMID:
25582667
39.

Seasonal variability in the incidence of carcinomatous meningitis.

Koutras A, Sakellakis M, Makatsoris T, Psachoulia C, Kardari M, Nikolakopoulos A, Gogos C, Kalofonos HP.

J Neurosurg. 2015 Mar;122(3):543-6. doi: 10.3171/2014.11.JNS14174. Epub 2015 Jan 9.

PMID:
25574572
40.

Current therapeutic leads for the treatment of melanoma: targeted immunotherapy in the post-genomic era.

Papanastasiou AD, Sirinian C, Kalofonos HP, Repanti M.

Curr Mol Pharmacol. 2014;7(1):33-43. Review.

PMID:
25563852
41.

The inhibition of aromatase alters the mechanical and rheological properties of non-small-cell lung cancer cell lines affecting cell migration.

Giannopoulou E, Siatis KE, Metsiou D, Kritikou I, Papachristou DJ, Kalofonou M, Koutras A, Athanassiou G, Kalofonos HP.

Biochim Biophys Acta. 2015 Feb;1853(2):328-37. doi: 10.1016/j.bbamcr.2014.11.016. Epub 2014 Nov 18.

42.

Bortezomib-induced peripheral neurotoxicity: an update.

Argyriou AA, Cavaletti G, Bruna J, Kyritsis AP, Kalofonos HP.

Arch Toxicol. 2014 Sep;88(9):1669-79. doi: 10.1007/s00204-014-1316-5. Epub 2014 Jul 29. Review.

PMID:
25069804
43.

Expression patterns of SDF1/CXCR4 in human invasive breast carcinoma and adjacent normal stroma: correlation with tumor clinicopathological parameters and patient survival.

Papatheodorou H, Papanastasiou AD, Sirinian C, Scopa C, Kalofonos HP, Leotsinidis M, Papadaki H.

Pathol Res Pract. 2014 Oct;210(10):662-7. doi: 10.1016/j.prp.2014.06.015. Epub 2014 Jun 27.

PMID:
25041836
44.

KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study.

Negru S, Papadopoulou E, Apessos A, Stanculeanu DL, Ciuleanu E, Volovat C, Croitoru A, Kakolyris S, Aravantinos G, Ziras N, Athanasiadis E, Touroutoglou N, Pavlidis N, Kalofonos HP, Nasioulas G.

BMJ Open. 2014 May 23;4(5):e004652. doi: 10.1136/bmjopen-2013-004652.

45.

Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study.

Griffith KA, Dorsey SG, Renn CL, Zhu S, Johantgen ME, Cornblath DR, Argyriou AA, Cavaletti G, Merkies IS, Alberti P, Postma TJ, Rossi E, Frigeni B, Bruna J, Velasco R, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey DJ, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG; CI-PeriNomS Group.

J Peripher Nerv Syst. 2014 Jun;19(2):127-35. doi: 10.1111/jns5.12064.

46.

Physicians' brain drain in Greece: a perspective on the reasons why and how to address it.

Ifanti AA, Argyriou AA, Kalofonou FH, Kalofonos HP.

Health Policy. 2014 Aug;117(2):210-5. doi: 10.1016/j.healthpol.2014.03.014. Epub 2014 Apr 12. Review.

PMID:
24794987
47.

Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature.

Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP.

Cancer Manag Res. 2014 Mar 19;6:135-47. doi: 10.2147/CMAR.S44261. eCollection 2014. Review.

48.

Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin.

Alberti P, Rossi E, Cornblath DR, Merkies IS, Postma TJ, Frigeni B, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, Cavaletti G; CI-PeriNomS Group.

Ann Oncol. 2014 Jan;25(1):257-64. doi: 10.1093/annonc/mdt409. Epub 2013 Nov 19.

49.

Serglycin is implicated in the promotion of aggressive phenotype of breast cancer cells.

Korpetinou A, Skandalis SS, Moustakas A, Happonen KE, Tveit H, Prydz K, Labropoulou VT, Giannopoulou E, Kalofonos HP, Blom AM, Karamanos NK, Theocharis AD.

PLoS One. 2013 Oct 31;8(10):e78157. doi: 10.1371/journal.pone.0078157. eCollection 2013.

50.

The combination of antitumor drugs, exemestane and erlotinib, induced resistance mechanism in H358 and A549 non-small cell lung cancer (NSCLC) cell lines.

Kritikou I, Giannopoulou E, Koutras AK, Labropoulou VT, Kalofonos HP.

Pharm Biol. 2013 Nov 5. [Epub ahead of print]

PMID:
24192333

Supplemental Content

Loading ...
Support Center